MYRIAD GENETICS INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that MYRIAD GENETICS INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Jun 30, 2017 | $771.40M | Aug 9, 2017 |
| FY2017 | Jun 30, 2016 | $753.80M | Aug 9, 2017 |
| FY2017 | Jun 30, 2015 | $723.10M | Aug 9, 2017 |
| FY2016 | Jun 30, 2014 | $778.20M | Aug 10, 2016 |
| FY2015 | Jun 30, 2013 | $613.20M | Aug 12, 2015 |
| FY2014 | Jun 30, 2012 | $496.01M | Aug 13, 2014 |
| FY2013 | Jun 30, 2011 | $402.08M | Aug 14, 2013 |
| FY2012 | Jun 30, 2010 | $362.65M | Aug 15, 2012 |
| FY2011 | Jun 30, 2009 | $326.53M | Aug 15, 2011 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $824.50M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $837.60M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $753.20M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $678.40M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $690.60M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $299.80M | Mar 1, 2023 |
| FY2020 | Jun 30, 2020 | $93.20M | Aug 13, 2020 |
| FY2020 | Mar 31, 2020 | $164.00M | Aug 13, 2020 |
| FY2020 | Dec 31, 2019 | $195.10M | Aug 13, 2020 |
| FY2020 | Sep 30, 2019 | $186.30M | Aug 13, 2020 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $576.60M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $585.40M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $517.00M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $476.40M | Feb 28, 2025 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($365.90M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | ($127.30M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | ($263.30M) | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | ($112.00M) | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | ($27.20M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | ($53.10M) | Mar 1, 2023 |
| FY2020 | Jun 30, 2020 | ($55.40M) | Aug 13, 2020 |
| FY2020 | Mar 31, 2020 | ($115.20M) | Aug 13, 2020 |
| FY2020 | Dec 31, 2019 | ($8.30M) | Aug 13, 2020 |
| FY2020 | Sep 30, 2019 | ($20.60M) | Aug 13, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($387.20M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | ($123.50M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | ($257.40M) | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | ($140.60M) | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | ($190.50M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | ($87.80M) | Mar 1, 2023 |
| FY2020 | Jun 30, 2020 | ($68.30M) | Aug 13, 2020 |
| FY2020 | Mar 31, 2020 | ($133.70M) | Aug 13, 2020 |
| FY2020 | Dec 31, 2019 | ($8.80M) | Aug 13, 2020 |
| FY2020 | Sep 30, 2019 | ($20.90M) | Aug 13, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $106.80M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $113.40M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $88.70M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $85.40M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $81.90M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $35.80M | Mar 1, 2023 |
| FY2020 | Jun 30, 2020 | $17.40M | Aug 13, 2020 |
| FY2020 | Mar 31, 2020 | $19.70M | Aug 13, 2020 |
| FY2020 | Dec 31, 2019 | $18.80M | Aug 13, 2020 |
| FY2020 | Sep 30, 2019 | $21.30M | Aug 13, 2020 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $572.90M | Feb 28, 2024 |
| FY2023 | Dec 31, 2022 | $514.70M | Feb 28, 2024 |
| FY2023 | Dec 31, 2021 | $537.80M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $260.40M | Mar 1, 2023 |
| FY2020 | Jun 30, 2020 | $107.40M | Aug 13, 2020 |
| FY2020 | Mar 31, 2020 | $132.90M | Aug 13, 2020 |
| FY2020 | Dec 31, 2019 | $134.30M | Aug 13, 2020 |
| FY2020 | Sep 30, 2019 | $135.50M | Aug 13, 2020 |
| FY2020 | Jun 30, 2019 | $149.80M | Aug 13, 2020 |
| FY2020 | Mar 31, 2019 | $140.60M | Aug 13, 2020 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.80M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | ($8.70M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | ($110.90M) | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | ($106.30M) | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $18.60M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | ($73.70M) | Mar 1, 2023 |
| FY2022 | Jun 30, 2020 | $60.70M | Mar 1, 2023 |
| FY2021 | Jun 30, 2019 | $83.70M | Feb 25, 2022 |
| FY2020 | Jun 30, 2018 | $115.90M | Aug 13, 2020 |
| FY2019 | Jun 30, 2017 | $106.20M | Aug 13, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $706.60M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $1.03B | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $1.15B | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $1.20B | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $1.32B | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $1.42B | Feb 25, 2022 |
| FY2020 | Jun 30, 2020 | $1.40B | Aug 13, 2020 |
| FY2020 | Jun 30, 2019 | $1.56B | Aug 13, 2020 |
| FY2019 | Jun 30, 2018 | $1.18B | Aug 13, 2019 |
| FY2018 | Jun 30, 2017 | $1.21B | Aug 24, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $338.60M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $326.50M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $363.30M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $312.90M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $352.90M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $537.80M | Feb 25, 2022 |
| FY2020 | Jun 30, 2020 | $486.40M | Aug 13, 2020 |
| FY2020 | Jun 30, 2019 | $473.80M | Aug 13, 2020 |
| FY2019 | Jun 30, 2018 | $209.20M | Aug 13, 2019 |
| FY2018 | Jun 30, 2017 | $440.90M | Aug 24, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $368.00M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $701.10M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $783.20M | Feb 24, 2026 |
| FY2025 | Dec 31, 2022 | $885.80M | Feb 24, 2026 |
| FY2024 | Dec 31, 2021 | $967.80M | Feb 28, 2025 |
| FY2023 | Dec 31, 2020 | $881.00M | Feb 28, 2024 |
| FY2020 | Jun 30, 2020 | $918.20M | Aug 13, 2020 |
| FY2020 | Jun 30, 2019 | $1.09B | Aug 13, 2020 |
| FY2019 | Jun 30, 2018 | $966.10M | Aug 13, 2019 |
| FY2018 | Jun 30, 2017 | $768.40M | Aug 24, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $51.60M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $286.30M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $287.40M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $286.80M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $239.20M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $329.20M | Feb 25, 2022 |
| FY2020 | Jun 30, 2020 | $327.60M | Aug 13, 2020 |
| FY2020 | Jun 30, 2019 | $417.20M | Aug 13, 2020 |
| FY2020 | Jun 30, 2018 | $318.60M | Aug 13, 2020 |
| FY2019 | Jun 30, 2017 | $316.10M | Aug 13, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.12B) | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | ($756.80M) | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | ($629.50M) | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | ($366.20M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | ($254.20M) | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | ($227.00M) | Feb 25, 2022 |
| FY2020 | Jun 30, 2020 | ($173.90M) | Aug 13, 2020 |
| FY2020 | Jun 30, 2019 | $25.60M | Aug 13, 2020 |
| FY2019 | Jun 30, 2018 | $54.10M | Aug 13, 2019 |
| FY2019 | Jun 30, 2017 | ($79.20M) | Aug 13, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $149.60M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $102.40M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $132.10M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $56.90M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $257.40M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $117.00M | Mar 1, 2023 |
| FY2022 | Jun 30, 2020 | $163.70M | Mar 1, 2023 |
| FY2020 | Jun 30, 2019 | $93.20M | Aug 13, 2020 |
| FY2019 | Jun 30, 2018 | $110.90M | Aug 13, 2019 |
| FY2019 | Jun 30, 2017 | $102.40M | Aug 13, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $119.90M | Feb 24, 2026 |
| FY2022 | Dec 31, 2022 | $0 | Mar 1, 2023 |
| FY2021 | Dec 31, 2021 | $0 | Feb 25, 2022 |
| FY2021 | Dec 31, 2020 | $224.80M | Feb 25, 2022 |
| FY2020 | Jun 30, 2020 | $224.40M | Aug 13, 2020 |
| FY2020 | Jun 30, 2019 | $233.50M | Aug 13, 2020 |
| FY2019 | Jun 30, 2018 | $9.30M | Aug 13, 2019 |
| FY2018 | Jun 30, 2017 | $99.10M | Aug 24, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (3) | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | (3) | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | (1) | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Mar 1, 2023 |
| FY2020 | Jun 30, 2020 | 0 | Aug 13, 2020 |
| FY2020 | Mar 31, 2020 | (1) | Aug 13, 2020 |
| FY2020 | Dec 31, 2019 | 0 | Aug 13, 2020 |
| FY2020 | Sep 30, 2019 | 0 | Aug 13, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (3) | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | (3) | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | (1) | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Mar 1, 2023 |
| FY2020 | Jun 30, 2020 | 0 | Aug 13, 2020 |
| FY2020 | Mar 31, 2020 | (1) | Aug 13, 2020 |
| FY2020 | Dec 31, 2019 | 0 | Aug 13, 2020 |
| FY2020 | Sep 30, 2019 | 0 | Aug 13, 2020 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 93.50M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | 91.30M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | 89.90M | Feb 24, 2026 |
| FY2025 | Dec 31, 2022 | 81.20M | Feb 24, 2026 |
| FY2024 | Dec 31, 2021 | 80.00M | Feb 28, 2025 |
| FY2023 | Dec 31, 2020 | 75.40M | Feb 28, 2024 |
| FY2022 | Jun 30, 2020 | 74.70M | Mar 1, 2023 |
| FY2022 | Jun 30, 2019 | 73.50M | Mar 1, 2023 |
| FY2021 | Jun 30, 2018 | 70.60M | Feb 25, 2022 |
| FY2020 | Jun 30, 2017 | 68.40M | Aug 13, 2020 |